Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: press clippings (2)

CEO, Michael Heltzen is interviewed by Jane King
heltzeninvestorpress clippingsvideo
Jane King interviews CEO, Michael Heltzen, in New YorkNovember 12, 2025
Lightning Rx, Colette Nataf
press clippings
Podcast: Lightning Rx' Colette Nataf interviews CEO Heltzen on future of biomanufacturingOctober 22, 2025
Podcast: 'The Catalyst' interviews CEO, Michael Heltzen
heltzenpress clippings
Podcast: 'The Catalyst' interviews CEO, Michael HeltzenOctober 17, 2025
Zachary Karl, Vice President Business Development @ Bio Innovations Midwest 2025
press clippingsvideo
World Bio Markets: AI - A tool U.S. industrial biomanufacturing cannot ignoreOctober 8, 2025
Inside Biotech podcast interviews CEO, Michael Heltzen
heltzenpress clippings
Podcast: 'Inside Biotech' interviews CEO, Michael HeltzenOctober 2, 2025
MDB Capital: eXoZymes & NCTx: The Breakthrough Opportunity with NCTx and Treating a Global Health Epidemic
heltzeninvestorpress clippingsvideo
MDB Capital: eXoZymes & NCTx: The Breakthrough Opportunity with NCTx and Treating a Global Health EpidemicSeptember 18, 2025
World Bio Markets: AI and Machine Learning - The Silver Bullet we Must Not Dodge
press clippingsvideo
World Bio Markets: AI and Machine Learning - The Silver Bullet we Must Not DodgeJuly 2, 2025
Chris Marlett, MDB Capital
investorpress clippingsvideo
Slack Capital interview: Chris Marlett, Chairman of the BoardMay 22, 2025
Slack Capital interview: Damien Perriman, CCO
investorpress clippingsvideo
Slack Capital interview: Damien Perriman, CCOMay 20, 2025
Michael Heltzen & Erum Azeez Khan
heltzenpress releaseinvestorpress clippings
Podcast: eXoZymes highlights scalable biomanufacturing platform and first spinout, NCTx, on 'Grow Everything'May 16, 2025
Previous page
Page 2 of 3
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark